Galectin Therapeutics Inc
GALT Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$3.19
KIRA · Stoqly’s AI analyst, in plain words
- Galectin Therapeutics Inc lost $30.8M in fiscal 2025.
Market cap
$210M
P/E
—
Revenue
—
Net income
−$30.8M
Free cash flow
—
Operating margin
—
Galectin Therapeutics Inc in 30 seconds · fiscal 2025
Does it make a profit?
−$30.8M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Galectin Therapeutics Inc does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 31, 2026
- Legal name
- GALECTIN THERAPEUTICS INC
- CIK
- 0001133416
Galectin Therapeutics Inc · GALT
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$30.5M | −$38.8M | −$41.1M | −$47.0M | −$30.8M |
| Diluted EPS | −$0.52 | −$0.65 | −$0.74 | −$0.76 | −$0.48 |
| Cash | |||||
| Cash from operations | −$24.3M | −$31.1M | −$33.0M | −$41.8M | −$23.9M |
| Share count change | 2.6% | 1.5% | 1.3% | 3.6% | 2.6% |
| Debt and strength | |||||
| Cash and short-term investments | $39.6M | $18.6M | $25.7M | $15.1M | $17.7M |
| Shareholders' equity | $0.9M | −$33.9M | −$62.0M | −$105M | −$128M |
| Current ratio | 4.6x | 1.6x | 1.8x | 0.5x | 2.4x |
| Interest coverage | −61.7x | −37.1x | −13.6x | −7.7x | −2.7x |
| Returns and quality | |||||
| Return on equity | −261.3% | — | — | — | — |
| Return on tangible equity | −3,437.6% | — | — | — | — |
| Altman Z'' | −20.8 | −57.9 | −48.0 | −98.8 | −76.2 |
Insiders bought, 12 months
$0.0M
2 insiders
Insiders sold, 12 months
$5.5M
6 insiders
Of sales under plans
77%
$4.2M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Galectin Therapeutics Inc · GALT
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $3.19 a share, the company is worth $210M.
Source: SEC EDGAR XBRL filings (CIK 0001133416). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.